If you have a certain type of multiple sclerosis (MS), your doctor might suggest Gilenya (fingolimod) as a treatment option for you. Gilenya is a prescription medication that’s used to treat the ...

Novartis got a reprieve last week when the U.S. Patent and Trademark Office upheld a patent on its multiple sclerosis blockbuster Gilenya. Now, the Swiss pharma intends to use that win in court ...

When an appeals board of the U.S. Patent and Trademark Office ruled Wednesday to uphold Novartis’ patent on multiple sclerosis drug Gilenya, it was also good news for rival Celgene. The decision ...

Biogen's Tecfidera is on its way to blockbuster status in the highly competitive multiple sclerosis indication. That's great news for Biogen, which needed the drug to succeed in order to protect its ...

ZURICH (Reuters) - Novartis has won a U.S. federal court order preventing rival generic makers from selling versions of the Swiss drugmaker's top-selling multiple sclerosis medicine Gilenya in the ...

Novartis has confirmed the latest global patient-use data which showed that Gilenya (fingolimod) has been used to treat more than 63,000 patients in clinical trials and the post-marketing setting.

The Food and Drug Administration is investigating a reported case of the brain infection progressive multifocal leukoencephalopathy in a patient taking the Novartis MS drug Gilenya in Europe. The ...

The FDA has approved Gilenya (fingolimod capsules, from Novartis), a sphingosine 1-phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis to ...

ZURICH, March 21 (Reuters) - Swiss drugmaker Novartis AG said the European Commission approved its multiple sclerosis pill Gilenya, a potential blockbuster that should help it cope with price ...

ZURICH, Dec 12 (Reuters) - Swiss drugmaker Novartis said on Monday it was investigating whether its multiple sclerosis pill Gilenya, a potential blockbuster, caused the death of a 59-year-old patient ...